Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Peter Lindsay Anderson

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-6128
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOP-Administration


    Collapse Research 
    Collapse research activities and funding
    R01AI064029     (ANDERSON, PETER LINDSAY)Mar 15, 2005 - Feb 28, 2011
    NIH/NIAID
    Sex and disease dependent nucleoside analog toxicity
    Role: Principal Investigator

    R03AI068438     (ANDERSON, PETER LINDSAY)Jul 15, 2006 - Jun 30, 2009
    NIH/NIAID
    Genetic-determinants of protease inhibitor pharmacology
    Role: Principal Investigator

    R34AI078776     (ANDERSON, PETER LINDSAY)May 1, 2008 - Apr 30, 2009
    NIH/NIAID
    Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis
    Role: Principal Investigator

    S10RR023442     (ANDERSON, PETER LINDSAY)Sep 30, 2008 - Sep 29, 2009
    NIH/NCRR
    UPLC-MS for pharmacology studies in HIV
    Role: Principal Investigator

    U01AI084735     (ANDERSON, PETER LINDSAY)Aug 15, 2009 - Jul 31, 2014
    NIH/NIAID
    Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis
    Role: Principal Investigator

    U01AI106499     (ANDERSON, PETER LINDSAY)Apr 15, 2013 - Mar 31, 2017
    NIH/NIAID
    PrEP and ART adherence monitoring using dried blood spots
    Role: Principal Investigator

    R01AI122298     (ANDERSON, PETER LINDSAY)Dec 1, 2015 - Nov 30, 2020
    NIH/NIAID
    Novel approaches for quantitative assessment of adherence
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL. Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opin Drug Metab Toxicol. 2017 Apr 03; 1-10. PMID: 28335648.
      View in: PubMed
    2. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. N Engl J Med. 2017 02 02; 376(5):501-502. PMID: 28146652.
      View in: PubMed
    3. Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clin Infect Dis. 2017 Feb 01; 64(3):317-325. PMID: 28013265.
      View in: PubMed
    4. Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS One. 2016; 11(11):e0165505. PMID: 27832147.
      View in: PubMed
    5. Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017 Feb; 72(2):478-485. PMID: 28073964.
      View in: PubMed
    6. Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ, Gardner EM, Macatangay BJ, Breen EC, Jacobson LP, Anderson PL, Wada NI. Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. Clin Infect Dis. 2016 Dec 15; 63(12):1661-1667. PMID: 27660234.
      View in: PubMed
    7. Chen X, McAllister KJ, Klein B, Bushman LR, Anderson PL. Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate. Biomed Chromatogr. 2017 Mar; 31(3). PMID: 27557296.
      View in: PubMed
    8. Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses. 2016 Oct/Nov; 32(10-11):981-991. PMID: 27526873.
      View in: PubMed
    9. Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ. A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells. Pharm Res. 2017 Jan; 34(1):73-83. PMID: 27633886.
      View in: PubMed
    10. Glidden DV, Anderson PL, Grant RM. Pharmacology supports on-demand PrEP. Lancet HIV. 2016 Sep; 3(9):e405-6. PMID: 27562738.
      View in: PubMed
    11. Chen X, Castillo-Mancilla JR, Seifert SM, McAllister KB, Zheng JH, Bushman LR, MaWhinney S, Anderson PL. Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother. 2016 Sep; 60(9):5387-92. PMID: 27353267.
      View in: PubMed
    12. Anderson PL, Reirden D, Castillo-Mancilla J. Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. J Acquir Immune Defic Syndr. 2016 Aug 15; 72 Suppl 3:S230-4. PMID: 27429188.
      View in: PubMed
    13. Wong TC, Lan A, Kiser JJ, Anderson PL, Patel K, Tillman H, Naggie S. Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. Hepatology. 2016 Sep; 64(3):999-1000. PMID: 26799354.
      View in: PubMed
    14. Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS. 2016 Mar 13; 30(5):743-51. PMID: 26605514.
      View in: PubMed
    15. Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18. PMID: 26892777.
      View in: PubMed
    16. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016 Jan; 176(1):75-84. PMID: 26571482.
      View in: PubMed
    17. Anderson PL, García-Lerma JG, Heneine W. Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2016 Jan; 11(1):94-101. PMID: 26633641.
      View in: PubMed
    18. Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016 Jan; 32(1):32-43. PMID: 26414912.
      View in: PubMed
    19. Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ. Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. Antimicrob Agents Chemother. 2015 Dec; 59(12):7671-9. PMID: 26416874.
      View in: PubMed
    20. Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. J Infect Dis. 2015 Dec 15; 212(12):1988-95. PMID: 26071566.
      View in: PubMed
    21. Meditz AL, Palmer C, Predhomme J, Searls K, Kerr B, Seifert S, Caraway P, Gardner EM, MaWhinney S, Anderson PL. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. AIDS Res Hum Retroviruses. 2015 Oct; 31(10):1015-22. PMID: 26059647.
      View in: PubMed
    22. Bjornstad P, Anderson PL, Maahs DM. Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. Acta Diabetol. 2016 Apr; 53(2):331-3. PMID: 25959420.
      View in: PubMed
    23. Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2015 Aug 15; 61(4):572-80. PMID: 25908682.
      View in: PubMed
    24. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis. 2015 Nov 01; 212(9):1402-6. PMID: 25895984.
      View in: PubMed
    25. Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr. 2015 Apr 15; 68(5):495-501. PMID: 25763783.
      View in: PubMed
    26. Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015 Apr; 59(4):2179-88. PMID: 25645847.
      View in: PubMed
    27. Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, Haberer JE, Rooney J, Hendrix CW, Anderson PL, Huang Y, Priddy F, Gandhi M. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015 Jan 01; 68(1):13-20. PMID: 25296098.
      View in: PubMed
    28. Jimmerson LC, Ray ML, Bushman LR, Anderson PL, Klein B, Rower JE, Zheng JH, Kiser JJ. Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26; 978-979:163-72. PMID: 25555148.
      View in: PubMed
    29. Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014 Dec 15; 67(5):528-37. PMID: 25230290.
      View in: PubMed
    30. Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, Bushman LR, Anderson PL, Meditz AL. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses. 2015 Apr; 31(4):428-32. PMID: 25328112.
      View in: PubMed
    31. Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Rower C, Klein B, Kerr BJ, Guida LA, Zheng JH, Bushman LR, Anderson PL. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis. 2015 Mar 01; 60(5):804-10. PMID: 25409469.
      View in: PubMed
    32. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):530-7. PMID: 24853306.
      View in: PubMed
    33. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep; 14(9):820-9. PMID: 25065857.
      View in: PubMed
    34. Maahs DM, Bushman L, Kerr B, Ellis SL, Pyle L, McFann K, Bouffard A, Bishop FK, Nguyen N, Anderson PL. A practical method to measure GFR in people with type 1 diabetes. J Diabetes Complications. 2014 Sep-Oct; 28(5):667-73. PMID: 25027389.
      View in: PubMed
    35. Anderson PL, Glidden DV, Bushman LR, Heneine W, García-Lerma JG. Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. J Antimicrob Chemother. 2014 Sep; 69(9):2470-6. PMID: 24862094.
      View in: PubMed
    36. Chen X, Bushman LR, McAllister KJ, Anderson PL, Kiser JJ. Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma. Biomed Chromatogr. 2014 Dec; 28(12):1714-21. PMID: 24760592.
      View in: PubMed
    37. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014 Oct 15; 210(8):1217-27. PMID: 24740633.
      View in: PubMed
    38. Czaja CA, Levin A, Moridani M, Krank JL, Curran-Everett D, Anderson PL. Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group. Antimicrob Agents Chemother. 2014 Jun; 58(6):3570-1. PMID: 24733469.
      View in: PubMed
    39. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736. PMID: 24421901.
      View in: PubMed
    40. Jimmerson LC, Zheng JH, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 01; 944:18-24. PMID: 24291608.
      View in: PubMed
    41. Zheng JH, Guida LA, Rower C, Castillo-Mancilla J, Meditz A, Klein B, Kerr BJ, Langness J, Bushman L, Kiser J, Anderson PL. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2014 Jan; 88:144-51. PMID: 24055850.
      View in: PubMed
    42. Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013 May; 9(5):573-88. PMID: 23514375.
      View in: PubMed
    43. Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 2012 Dec; 22(12):891-4. PMID: 22960662.
      View in: PubMed
    44. Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013 Feb; 29(2):384-90. PMID: 22935078.
      View in: PubMed
    45. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012 Sep 12; 4(151):151ra125. PMID: 22972843.
      View in: PubMed
    46. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8. PMID: 22331658.
      View in: PubMed
    47. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1227-34. PMID: 22394315.
      View in: PubMed
    48. Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother. 2012 Jun; 56(6):3011-9. PMID: 22391541.
      View in: PubMed
    49. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012 Nov; 52(11):1725-38. PMID: 22174437.
      View in: PubMed
    50. Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, Anderson PL. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011 Sep 10; 56(2):390-401. PMID: 21715120.
      View in: PubMed
    51. Rower JE, Klein B, Bushman LR, Anderson PL. Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr. 2012 Jan; 26(1):12-20. PMID: 21465499.
      View in: PubMed
    52. Wempe MF, Anderson PL. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos. 2011 Mar; 39(3):522-7. PMID: 21148251.
      View in: PubMed
    53. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb; 66(2):240-50. PMID: 21118913.
      View in: PubMed
    54. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30; 363(27):2587-99. PMID: 21091279.
      View in: PubMed
    55. Enomoto L, Anderson PL, Li S, Edelstein CL, Weinberg A. Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):47-55. PMID: 20929390.
      View in: PubMed
    56. Kiser JJ, Bumpass JB, Meditz AL, Anderson PL, Bushman L, Ray M, Predhomme JA, Rower J, Mawhinney S, Brundage R. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010 Dec; 54(12):4999-5003. PMID: 20921313.
      View in: PubMed
    57. Anderson PL, Rower JE. Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther. 2010; 2:a2004. PMID: 20953318.
      View in: PubMed
    58. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov; 64(5):1071-9. PMID: 19710077.
      View in: PubMed
    59. McRae M, Clay PG, Anderson PL, Glaros AG. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. Pharmacotherapy. 2009 Aug; 29(8):937-42. PMID: 19637947.
      View in: PubMed
    60. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009 Jun 01; 23(9):1035-46. PMID: 19381075.
      View in: PubMed
    61. Anderson PL, King T, Zheng JH, MaWhinney S. Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. J Antimicrob Chemother. 2008 Oct; 62(4):738-45. PMID: 18567572.
      View in: PubMed
    62. Anderson PL. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS. 2008 May; 3(3):258-65. PMID: 19372976.
      View in: PubMed
    63. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):298-303. PMID: 18398970.
      View in: PubMed
    64. Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007 Sep 12; 21(14):1849-54. PMID: 17721092.
      View in: PubMed
    65. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008 Feb; 83(2):265-72. PMID: 17597712.
      View in: PubMed
    66. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS. 2007 May 11; 21(8):1060-2. PMID: 17457108.
      View in: PubMed
    67. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 01; 42(4):441-9. PMID: 16791115.
      View in: PubMed
    68. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, Fletcher CV. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 07; 843(2):147-56. PMID: 16828350.
      View in: PubMed
    69. Anderson PL, Kakuda TN. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother. 2006 Jul; 58(1):220-1. PMID: 16717052.
      View in: PubMed
    70. Aquilante CL, Langaee TY, Anderson PL, Zineh I, Fletcher CV. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clin Chim Acta. 2006 Oct; 372(1-2):195-8. PMID: 16701601.
      View in: PubMed
    71. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006 Apr; 26(4):511-4. PMID: 16553510.
      View in: PubMed
    72. Kiser JJ, Anderson PL, Kakuda TN. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opin Pharmacother. 2006 Feb; 7(2):229-41. PMID: 16433587.
      View in: PubMed
    73. King T, Bushman L, Anderson PL, Delahunty T, Ray M, Fletcher CV. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 02; 831(1-2):248-57. PMID: 16412710.
      View in: PubMed
    74. Kiser JJ, Anderson PL, Gerber JG. Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs. Curr HIV/AIDS Rep. 2005 Jun; 2(2):61-7. PMID: 16091250.
      View in: PubMed
    75. Anderson PL. The ABC's of pharmacokinetics. Posit Aware. 2005; Spec No:4-7, 19. PMID: 15828101.
      View in: PubMed
    76. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS. 2004 Dec 03; 18(18):2442-4. PMID: 15622326.
      View in: PubMed
    77. Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother. 2004 Nov; 38(11):1924-34. PMID: 15479772.
      View in: PubMed
    78. Anderson PL, Fletcher CV. Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr HIV/AIDS Rep. 2004 Apr; 1(1):33-9. PMID: 16091221.
      View in: PubMed
    79. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004 Mar 01; 38(5):743-53. PMID: 14986261.
      View in: PubMed
    80. Anderson PL, Miller S, Bushman LR. Stability of zidovudine with oxytocin in a simulated Y-site injection. Am J Health Syst Pharm. 2004 Feb 15; 61(4):394-6. PMID: 15011769.
      View in: PubMed
    81. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003 Oct 17; 17(15):2159-68. PMID: 14523272.
      View in: PubMed
    82. Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clin Pharmacol Ther. 2002 Apr; 71(4):280-5. PMID: 11956511.
      View in: PubMed
    83. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002 Mar 08; 16(4):551-60. PMID: 11872998.
      View in: PubMed
    84. Anderson PL, Fletcher CV. Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors. Curr Infect Dis Rep. 2001 Aug; 3(4):381-387. PMID: 11470030.
      View in: PubMed
    85. Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother. 2001 Jan; 45(1):236-42. PMID: 11120972.
      View in: PubMed
    86. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV. Indinavir plasma protein binding in HIV-1-infected adults. AIDS. 2000 Oct 20; 14(15):2293-7. PMID: 11089617.
      View in: PubMed
    87. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000 Sep 29; 14(14):2137-44. PMID: 11061655.
      View in: PubMed
    88. Anderson PL, Noormohamed SE, Henry K, Brundage RC, Balfour HH, Fletcher CV. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy. 2000 Aug; 20(8):917-22. PMID: 10939552.
      View in: PubMed
    89. Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf. 2000 Aug; 23(2):131-42. PMID: 10945375.
      View in: PubMed
    90. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000 Jun; 30 Suppl 2:S151-9. PMID: 10860900.
      View in: PubMed
    91. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS. 1999 Nov 12; 13(16):2311-2. PMID: 10563722.
      View in: PubMed
    92. Strom TB, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion proteins. Ann N Y Acad Sci. 1991 Dec 30; 636:233-50. PMID: 1793213.
      View in: PubMed
    93. Strom TB, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion proteins. Semin Immunol. 1990 Nov; 2(6):467-79. PMID: 2104283.
      View in: PubMed
    Anderson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)